Vertex Drops Next-Generation Pain Drug After Phase 2 Failure, Casts Doubt on Broader Journavx Expansion on August 05, 2025 Acute onset pain Approved Drug Development Journavx non-opioid pain drugs Pain management Peripheral neuropathic pain Sodium Channel Blockers United States Food and Drug Administration VX-993 +